<DOC>
	<DOCNO>NCT00001598</DOCNO>
	<brief_summary>This study evaluate effectiveness male hormone dehydroepiandrosterone ( DHEA ) treat Sjogren 's syndrome . This autoimmune disorder , immune system attack salivary gland tear gland , affect primarily woman . Patients ' eye mouth become dry time , lead problem serious tooth decay eye irritation . Sex hormones seem influence immune response may help decrease disease severity . DHEA benefit patient two autoimmune disease , rheumatoid arthritis systemic lupus erythematosus . Women 18 75 year age Sjogren 's syndrome may eligible 7-month study . At initial visit , candidate physical examination , routine blood urine test eye dental examination , include test measure saliva production screening purpose establish baseline value participant . Those enrolled study randomly assign take either DHEA placebo ( look-alike tablet active ingredient ) day 6 month monitor follow-up visit month 1 , 3 , 6 7 . Physical examination , blood test urinalysis repeat month 1 , 3 , 6 7 ; saliva collect month 3 , 6 7 ; eye examine 3 6 month . Because hormone change may physical emotional effect , patient ask question mood , symptoms side effect treatment . It know Sjogren 's syndrome associate osteoporosis ( bone thinning ) , since condition occur autoimmune disorder , patient 's bone density measure first visit , blood drawn 3 6 month test various substance associate change bone density . A 24-hour urine collection first visit later urine test also test substance associate bone thinning .</brief_summary>
	<brief_title>DHEA Treatment Sjogren 's Syndrome</brief_title>
	<detailed_description>Primary Sjogren 's syndrome ( SS ) autoimmune disease chiefly affect exocrine gland . One troublesome manifestation SS severe salivary gland dysfunction . There accepted treatment underlie autoimmune reactivity salivary gland dysfunction SS . SS , well many autoimmune disease , predominantly affect woman . Although sex hormone cause SS autoimmune disease , appear influence immunological response ultimately severity disease . We propose test effect dehydroepiandrosterone ( DHEA ) , mildly androgenic adrenal hormone , lacrimal salivary gland function SS . In randomized , double-masked , outpatient protocol , patient receive DHEA 6 month . Efficacy treatment assess monitoring salivary lacrimal function , serological marker autoimmune activity , subjective report local systemic symptom .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Salivary Gland Diseases</mesh_term>
	<mesh_term>Lacrimal Apparatus Diseases</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Females diagnosis Primary Sjogren 's Syndrome . No history breast cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>Xerostomia</keyword>
	<keyword>Autoimmunity</keyword>
	<keyword>Salivary Glands</keyword>
	<keyword>Androgen Therapy</keyword>
	<keyword>Lacrimal Function</keyword>
	<keyword>DHEA</keyword>
	<keyword>Sjogren 's Syndrome</keyword>
	<keyword>Dehydroepiandrosterone</keyword>
</DOC>